OPR - Delayed Quote • USD XOMA Jun 2024 25.000 call (XOMA240621C00025000) Follow 0.8500 0.0000 (0.00%) At close: February 5 at 9:45 AM EST Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for XOMA240621C00025000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: XOMA XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) Actym Therapeutics Appoints Thomas Smart as CEO XOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five years XOMA Corporation Announces Closing of Tender Offer XOMA Declares Quarterly Preferred Stock Dividends XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023 XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value XOMA to Present at Upcoming Investor Conferences in March XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right With 37% ownership, XOMA Corporation (NASDAQ:XOMA) has piqued the interest of institutional investors XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
